Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
IVIG for Small Fiber Neuropathy
Recruiting0 awardsPhase 2
Detroit, Michigan
This trial will enroll patients with small fiber neuropathy (SFN) to study the effects of an IVIG called Panzyga. Panzyga is approved by the FDA as a therapy for Primary humoral immunodeficiency (PI), Chronic immune thrombocytopenia (ITP), and Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults, but it has not been approved by the FDA for use in SFN.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.